key: cord-1034811-g9nku07y
authors: Maranger, Roxane
title: Message from the President: What Has COVID‐19 Taught Us about Science?
date: 2021-02-03
journal: Limnol Oceanogr Bull
DOI: 10.1002/lob.10428
sha: 8b90efc208a154d9262c51754e8fbe2d61d57072
doc_id: 1034811
cord_uid: g9nku07y

nan

I am writing this message on 14 December 2020. What a difficult year it has been. As of today, over 1.6 million people have died of COVID-19 as a function of the spread of SARS-CoV-2 in this global pandemic. On behalf of ASLO, I wish to extend my sincerest condolences to all members of the aquatic community who have lost family members or to those who have been seriously adversely affected by this terrible infectious disease. It is a very dark time. We have all been affected to some degree, but to quote Greta Thunberg on climate change: "We are all in the same storm. But we are not all in the same boat." This speaks to the inequities of how different demographics have been affected and challenged during this time. Many people have lost their jobs; it has been a struggle for many business sectors; divorce rates are high; front line workers in the health and essential service sectors are exhausted and continue to take risks. In academia, people of color and women with young children and older parents have been most adversely affected in terms of the ability to keep up with professional demands, and graduate students are suffering with high rates of depression (Gabster et al. 2020; Malish et al. 2020; Zahneis and June 2020) . This is not an exhaustive list of the many challenges faced. New cases are spiking all over the world, and we are headed in lockdown for the Christmas holidays. We can all conclude that 2020 has been a difficult year.

There is however hope on the horizon for 2021 and that hope is thanks to a global effort in scientific discovery and rapid communication. This includes the processes designed and the people involved to set up accelerated discovery in order to work together to find ways to combat COVID-19 for the benefit of the commons. So the purpose of this Bulletin article is to reflect on some of the more positive outcomes from this major global crisis. These thoughts come off the heels of a rather inspiring workshop I had the privilege to attend as part of the Council of Society Scientific Presidents (CSSP) a week or so ago, as well as the exchanges I have been able to have with my microbiologist life partner who works in drug development research. As such, these are more personal reflections on what mechanisms helped enable our accelerated understanding of COVID-19 leading to solution pathways, with the additional thought of what can ASLO as a community of aquatic scientists learn and possibly enable to address the multiple pressing issues facing our precious water resources.

From a drug discovery perspective, there was an unprecedented effort to mobilize and open the science needed to develop several vaccines in record time. SARS-CoV-2 was first sequenced in January 2020, and the first vaccine against COVID-19 developed by Pfizer-BioNTech was approved last week. As I write this message, the first vaccines are being administered to health professionals here in Canada as well as in other countries with appropriate storage facilities. Britain was the first to begin the process of administrating the vaccine a week earlier. There are two more vaccines that should be approved shortly that will facilitate broader distribution as they do not have the same refrigeration constraints (Moderna's is stored at −20 C whereas Oxford-AstraZeneca's can be refrigerated) and can be manufactured at lower cost, but supposedly perform with the same high degree of efficacy. The process of approval was fast tracked, but remains rigorous in that approval must achieve certain targets. There are mechanisms in place to ensure scientific rigor and a robust regulatory review during the rolling submission process as additional information on safety, efficacy, and quality accrues. Three vaccines approved within a year of disease discovery surpassed the most optimistic targets.

How did this happen? Science and business are largely competitive endeavors. However, to solve wicked problems, rapidly, we all know that this requires collaboration. Now for competition to bring out the best in all of us, some level of collaboration and shared knowledge is required. Enter the term coopetition: a strategic alliance that fosters cooperation among competitors (Bengtsson and Kock 2000) . The stakes were too high and the collective purpose was clear: we are in a global health crisis. To resolve it requires the rapid development and administration of vaccines to billions of people. As such, a strategic approach that involved a public-private partnership called ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) spearheaded by the U.S. National Institutes of Health (NIH) to bring all the strengths together from the different sectors to help in this time of urgency was formed (Corey et al. 2020 ). This involved major investments to several different pharmaceutical companies to facilitate the development of, or the clinical trial of, or the buying of approved vaccines while getting the community to work together by sharing essential information was key. It also involved getting them to work on multiple solution pathways for broader global administration. To accelerate vaccine discovery, this involved information sharing and harmonizing protocols, which included a common data and safety monitoring board, common primary and secondary targets, and common parameters to use as correlates of immunity. This enabled the "COVID-19 pivot" and a concerted effort in discovery where researchers from around the world were able to adapt their fundamental research to help in the search for an effective vaccine.

The COVID-19 pivot also resulted in a huge amount of discovery about the epidemiology of the disease, how quickly the virus has spread, the main transmission pathways, and its origins and ecology. In fact there was such an onslaught of scientific information; this has pushed the frontiers of Artificial Intelligence to sift through a large amount of information permitting for more rapid synthesis (Brainard 2020) . Used diligently and ethically, this will become such an asset to all future discovery as machines will be able to process more information much faster than humans. Increasing access to supercomputing also became a necessary asset on the road to accelerated discovery. During the pandemic, Dario Gil, Scientific Director of IBM, codeveloped and codesigned the COVID-19 High Performance Computing Consortium to help facilitate research to combat the pandemic. The consortium of 43 member institutions is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy, and IBM to bring together federal government, industry, and academic leaders who are volunteering free computer time and resources on their worldclass machines. As of today, this initiative has supported 95 different projects that must adhere to open science principles at 6.8 million CPU cores, again accelerating discovery on multiple frontiers.

My "coup de coeur" initiatives ("coup de coeur" is tough to translate-closest to my heart perhaps), however, are more grassroots but again embedded in the practice of working open. Both scientific initiatives were recognized and awarded by the CSSP for their vision in further accelerating discovery through the development of platforms and models for disseminating valuable information in meaningful ways in the face of this pandemic. One was the interactive dashboard that tracked COVID-19 cases around the world initiated by Lauren Gardner, codirector of the Center for Systems Science and Engineering at Johns Hopkins University. Out of that open data and information initiative, the data were used in over 2000 other publications! Open access enabled the creative use of that data from users around the world, more so than the original creators could have ever imagined. The data visualizations were powerful and understandable to the nonscientist; I tracked it daily for months and smiled when my musician brother from Germany shared it with my family. A second was the team from the University of Washington's Institute for Health Metrics and Evaluation (IHME) that established and continued to develop models to forecast COVID-19 outcomes for public health. This initiative developed as a response to requests from the UW's School of Medicine et al working to determine when COVID-19 would overwhelm the ability of their hospital systems to care for patients. The forecasts developed by IHME show demand for hospital services, daily and cumulative deaths due to COVID-19, rates of infection and testing, and the impact of social distancing, organized by country and state, with additional forecasts projected from countries around the globe. A handful of people started the initiative but this has now grown into a collective of over 500 people involved! Their models are in constant development and trying to integrate the best available knowledge, now including the use of vaccines to help better understand outcomes.

In his recent article in the Altantic entitled "How Science Beat the Virus and what it lost in the process," Ed Yong (2020), an award winning science writer, presents a more balanced picture of the good and the bad. He states: "At its best, science is a self-correcting march toward greater knowledge for the betterment of humanity. At its worst, it is a self-interested pursuit of greater prestige at the cost of truth and rigor. The pandemic brought both aspects to the fore. Humanity will benefit from the products of the COVID-19 pivot. Science itself will too, if it learns from the experience." Although there were scientific opportunists playing the game, a great amount of useful knowledge and science was developed and concerted to help towards a major global problem that should inspire us to think of how we can work differently into the future. What are some of the take home messages in positively mobilizing science to combat COVID-19? How can this be translated into wicked problems such as eutrophication, fisheries depletion, or more climate related concerns such as coastal sea level rise and ocean acidification? The following ideas are certainly not a final or complete list, but a beginning.

First, purpose must be the leader. Here the purpose was clear-there is a global health threat and we all needed to work towards a solution. There is no room for ego. Second, we need to work openly. We need the vision to rapidly collate and share information openly to accelerate discovery; this must become common practice and we need more resources and incentives to do so. Third, money. There is no doubt that financial resources matter which is why these public and private partnerships were so fruitful. But it was the combination of large and small injections of money combined with open practices that tipped the balance. Great science can come from anyone, anywhere. So both large and small initiatives should be supported and open practices favor this. Finally, effective scientific communication and political will. This was patchy of course and we must reflect on how to do this better, but by comparison to the Spanish Flu Pandemic when there were limited ways to communicate or share valuable scientific information, a much greater proportion of the population perished. We need to also consider the number of people whose lives were saved as a function of this.

The world is still on hold as the vaccination process slowly begins. We must remain patient and diligent despite the COVID-19 fatigue in all of us. That said, this is a defining moment for society and a defining moment for science. Perhaps it is our opportunity to rebuild public trust in science and work together in new ways to accelerate finding applicable solutions to the world's most wicked environmental problems. I invite you as ASLO members to imagine ways scientific societies can help to enable processes for accelerated scientific discovery to address pressing issues and to please share them with me.

Coopetition" in business networks-to cooperate and compete simultaneously

Scientists are drowning in COVID-19 papers. Can new tools keep them afloat? Science

2020. A strategic approach to COVID-19 vaccine R&D

Challenges for the female academic during the COVID-19 pandemic

In the wake of COVID-19, academia needs new solutions to ensure gender equity

How has the pandemic affected graduate students? This study has answers. The Chronicle of Higher Education

How science beat the virus and what it lost in the process. The Atlantic